[
  {
    "ts": null,
    "headline": "Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat",
    "summary": "Vertex stock dipped late Monday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older cystic fibrosis treatment, Trikafta.",
    "url": "https://finnhub.io/api/news?id=88d5a213d6ceba7226531709457f8abf6302c5433c27a1a9d8ffaca71d5b4524",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762212099,
      "headline": "Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat",
      "id": 137312462,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex stock dipped late Monday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older cystic fibrosis treatment, Trikafta.",
      "url": "https://finnhub.io/api/news?id=88d5a213d6ceba7226531709457f8abf6302c5433c27a1a9d8ffaca71d5b4524"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated 2025 Q3 - Results - Earnings Call Presentation",
    "summary": "2025-11-03. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2025 Q3 earnings call.",
    "url": "https://finnhub.io/api/news?id=d5040f1f1448d3a10197500b66d12ea1561b75eeab6708055cd132807b6939e2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762211298,
      "headline": "Vertex Pharmaceuticals Incorporated 2025 Q3 - Results - Earnings Call Presentation",
      "id": 137309473,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "2025-11-03. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2025 Q3 earnings call.",
      "url": "https://finnhub.io/api/news?id=d5040f1f1448d3a10197500b66d12ea1561b75eeab6708055cd132807b6939e2"
    }
  },
  {
    "ts": null,
    "headline": "Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates",
    "summary": "Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=6068c07660cf4287e1d41e7bba12ed42e11f7e523f35ee9f23b699101f119a2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762209002,
      "headline": "Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates",
      "id": 137312463,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=6068c07660cf4287e1d41e7bba12ed42e11f7e523f35ee9f23b699101f119a2c"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates",
    "summary": "Vertex (VRTX) delivered earnings and revenue surprises of +5.49% and +1.14%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=c56cb1f9124fff8251900a64e9f3ab9401e3f70f4423fc5235b86e8ac5eb7bc6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762208104,
      "headline": "Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates",
      "id": 137312464,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) delivered earnings and revenue surprises of +5.49% and +1.14%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=c56cb1f9124fff8251900a64e9f3ab9401e3f70f4423fc5235b86e8ac5eb7bc6"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call Transcript",
    "summary": "Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call November 3, 2025 4:30 PM ESTCompany ParticipantsSusie Lisa - Senior Vice President of...",
    "url": "https://finnhub.io/api/news?id=484ffce7d2d3632efd138a597a7d88a3c8720919e9606408b67dd6bf4d3d8852",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762207585,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call Transcript",
      "id": 137309085,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call November 3, 2025 4:30 PM ESTCompany ParticipantsSusie Lisa - Senior Vice President of...",
      "url": "https://finnhub.io/api/news?id=484ffce7d2d3632efd138a597a7d88a3c8720919e9606408b67dd6bf4d3d8852"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations",
    "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11.95 billion at the midpoint. Its non-GAAP profit of $4.80 per share was 4.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=2a0a923da184b888bd964c44a28e9076a1914a3b33185e64f843880c880f29ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762206255,
      "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations",
      "id": 137312465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11.95 billion at the midpoint. Its non-GAAP profit of $4.80 per share was 4.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=2a0a923da184b888bd964c44a28e9076a1914a3b33185e64f843880c880f29ef"
    }
  },
  {
    "ts": null,
    "headline": "Vertex: Q3 Earnings Snapshot",
    "summary": "On a per-share basis, the Boston-based company said it had profit of $4.20. Earnings, adjusted for one-time gains and costs, were $4.80 per share. The results exceeded Wall Street expectations.",
    "url": "https://finnhub.io/api/news?id=9e8418563f1a98c4244fb66b852b669874f66ace206e4753c0e1e4b3b13ea57e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762204262,
      "headline": "Vertex: Q3 Earnings Snapshot",
      "id": 137312466,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "On a per-share basis, the Boston-based company said it had profit of $4.20. Earnings, adjusted for one-time gains and costs, were $4.80 per share. The results exceeded Wall Street expectations.",
      "url": "https://finnhub.io/api/news?id=9e8418563f1a98c4244fb66b852b669874f66ace206e4753c0e1e4b3b13ea57e"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Reports Third Quarter 2025 Financial Results",
    "summary": "BOSTON, November 03, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.",
    "url": "https://finnhub.io/api/news?id=26553a28e7773153e1fcf91aaa22f7501433d4fe94e0ae3b50243f660c0e3db1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762203720,
      "headline": "Vertex Reports Third Quarter 2025 Financial Results",
      "id": 137312467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, November 03, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.",
      "url": "https://finnhub.io/api/news?id=26553a28e7773153e1fcf91aaa22f7501433d4fe94e0ae3b50243f660c0e3db1"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs",
    "summary": "Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs",
    "url": "https://finnhub.io/api/news?id=c2fbd89da5d8e3fd110f68d21e4ade3c48687ce0d9f34dfd70273406b2310c4a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762187340,
      "headline": "Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs",
      "id": 137320118,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs",
      "url": "https://finnhub.io/api/news?id=c2fbd89da5d8e3fd110f68d21e4ade3c48687ce0d9f34dfd70273406b2310c4a"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Stocks Rise To Start Week As Tylenol Maker Kenvue Inks $48.7 Billion Megadeal",
    "summary": "This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Monday. This is TheStreet’s Stock Market Today for Nov. 3, 2025. You can follow the latest updates on the market ...",
    "url": "https://finnhub.io/api/news?id=a088b180d8e4d880c6263a4429547ad50f5f780a991a25333813a24d40352eb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762187164,
      "headline": "Stock Market Today: Stocks Rise To Start Week As Tylenol Maker Kenvue Inks $48.7 Billion Megadeal",
      "id": 137303276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Monday. This is TheStreet’s Stock Market Today for Nov. 3, 2025. You can follow the latest updates on the market ...",
      "url": "https://finnhub.io/api/news?id=a088b180d8e4d880c6263a4429547ad50f5f780a991a25333813a24d40352eb9"
    }
  },
  {
    "ts": null,
    "headline": "Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?",
    "summary": "CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.",
    "url": "https://finnhub.io/api/news?id=f7425465ccfeaffc359080d622b8c5bbc3d5a7929370b5e117954ac0d00367c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762182660,
      "headline": "Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?",
      "id": 137312469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.",
      "url": "https://finnhub.io/api/news?id=f7425465ccfeaffc359080d622b8c5bbc3d5a7929370b5e117954ac0d00367c4"
    }
  },
  {
    "ts": null,
    "headline": "2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon",
    "summary": "These healthcare stocks are making strides in very important ways.",
    "url": "https://finnhub.io/api/news?id=59006f8b9732c67b65707dea79cabc39f01af7c2d8bd1fdc4fbbb58f86187d73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762173420,
      "headline": "2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon",
      "id": 137303026,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "These healthcare stocks are making strides in very important ways.",
      "url": "https://finnhub.io/api/news?id=59006f8b9732c67b65707dea79cabc39f01af7c2d8bd1fdc4fbbb58f86187d73"
    }
  },
  {
    "ts": null,
    "headline": "McDonald’s Earnings, Tariff Update, Musk Pay Vote: What to Watch This Week",
    "summary": "Following President Trump's return from Asia, eyes are on whether an end to the government shutdown is in sight. Meanwhile, investors will dig into earnings from McDonald’s, Palantir and a host of other companies.",
    "url": "https://finnhub.io/api/news?id=ff8d2f32b639a1e96b557372561eb0ebd65fbd9227ae0f2adb2141eb5941029f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762155774,
      "headline": "McDonald’s Earnings, Tariff Update, Musk Pay Vote: What to Watch This Week",
      "id": 137302131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Following President Trump's return from Asia, eyes are on whether an end to the government shutdown is in sight. Meanwhile, investors will dig into earnings from McDonald’s, Palantir and a host of other companies.",
      "url": "https://finnhub.io/api/news?id=ff8d2f32b639a1e96b557372561eb0ebd65fbd9227ae0f2adb2141eb5941029f"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX): Exploring Valuation After Promising Kidney Therapy Results and Growth in New Treatments",
    "summary": "Vertex Pharmaceuticals (VRTX) is gaining attention as new clinical data for its kidney disease therapy, povetacicept, shows encouraging results. The company’s portfolio is also benefiting from steady cystic fibrosis sales and early momentum from its latest treatments. See our latest analysis for Vertex Pharmaceuticals. The excitement around Vertex’s kidney therapy news comes as share price momentum has started building again, with a 1-month share price return of 5.5% and year-to-date gains of...",
    "url": "https://finnhub.io/api/news?id=22135c63b1af04de4c2049f96390e55823b0ca08e9b87432dd7efc1cc9e0eeef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762128851,
      "headline": "Vertex Pharmaceuticals (VRTX): Exploring Valuation After Promising Kidney Therapy Results and Growth in New Treatments",
      "id": 137303086,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) is gaining attention as new clinical data for its kidney disease therapy, povetacicept, shows encouraging results. The company’s portfolio is also benefiting from steady cystic fibrosis sales and early momentum from its latest treatments. See our latest analysis for Vertex Pharmaceuticals. The excitement around Vertex’s kidney therapy news comes as share price momentum has started building again, with a 1-month share price return of 5.5% and year-to-date gains of...",
      "url": "https://finnhub.io/api/news?id=22135c63b1af04de4c2049f96390e55823b0ca08e9b87432dd7efc1cc9e0eeef"
    }
  }
]